Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics

Frederic St-Denis-Bissonnette; Melanie Kirkby; Lisheng Wang; Jessie  R. Lavoie

doi:10.3791/67227

Journal

Recherche en cancérologie

Standardized Biomanufacturing and Characterization of NK-Extracellular Vesicles

August 16, 2024

Author Spotlight: Scalable Isolation and Production of Therapeutic Immune Cell-Derived Vesicles for Solid Tumor Treatment

00:00 min

•

102 Views

Frederic St-Denis-Bissonnette*^1,2, Melanie Kirkby*^1,2, Lisheng Wang^2,3,4, Jessie R. Lavoie^1,2

¹Biologic and Radiopharmaceutical Drugs Directorate, ²Department of Biochemistry, Microbiology and Immunology Institute,University of Ottawa, ³Centre for Infection, Immunity and Inflammation Institute,University of Ottawa, ⁴Regenerative Medicine Program,Ottawa Hospital Research Institute

Summary

Natural killer cell-derived extracellular vesicles (NK-EVs) hold promising potential as cancer biotherapeutics. This methodology-based study presents a scalable closed-loop biomanufacturing workflow designed to continuously produce and isolate large quantities of high-purity NK-EVs. In-process control testing is performed throughout the biomanufacturing workflow, ensuring the EVs meet quality standards for product release.

Standardized Biomanufacturing and Characterization of NK-Extracellular Vesicles

Author Spotlight: Scalable Isolation and Production of Therapeutic Immune Cell-Derived Vesicles for Solid Tumor Treatment

Summary

Article